HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide

HCID 178594084
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1402345-92-9
Standard SMILES
COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F
InChIKey
MSRFVAYVUUHQCN-UHFFFAOYSA-N
Molecular formula
C27H18F5N5O4S
Average molar mass
603.5 g/mol
Monoisotopic mass
603.09996606

Names & identifiers

Preferred name
5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide
IUPAC
5-[2-amino-4-oxo-3-[2-(trifluoromethyl)phenyl]quinazolin-6-yl]-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide
English name
GSK-F1
Molecular formula
C27H18F5N5O4S
Molecular weight
603.52

Names & synonyms

GSK-F11402345-92-91384097-27-15-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamidePI4KA inhibitor-F1(S)-GSK-F1CHEMBL3121308(3S)-GSK-F15-[2-amino-4-oxo-3-[2-(trifluoromethyl)phenyl]quinazolin-6-yl]-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide3-Pyridinesulfonamide, 5-[2-amino-3,4-dihydro-4-oxo-3-[2-(trifluoromethyl)phenyl]-6-quinazolinyl]-N-(2,4-difluorophenyl)-2-methoxy-5-{2-amino-4-oxo-3-[2-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-6-yl}-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamideC27H18F5N5O4S
Show more names
CS-2666GSK-F1, 10 mM in DMSO5-{2-Amino-4-oxo-3-[2-(trifluoromethyl)phenyl]-3,4-dihydro-6-quinazolinyl}-N-(2,4-difluorophenyl)-2-methoxy-3-pyridinesulfonamidehepatitis C virus,Phosphoinositide 3-kinase,Inhibitor,HEK293-AT1 cells,GSK-F-1,PI4K,Phosphatidylinositol 4 kinases,GSK-F1,HCV,GSKF1,COS-7,inhibit,GSK F1,PI4 kinases,PI3K

Properties

Computed structural propertiesFilling in

XLogP
4.3
Topological polar surface area
135 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
12
Rotatable bonds
6
Heavy atoms
42
Formal charge
0
Complexity
1,120

Physicochemical properties

Boiling point
744.3 · 744.3±70.0 °C(Predicted)
Density
1.55 · 1.55±0.1 g/cm3(Predicted)
storage temp.
-20 °C, · Store at -20°C, sealed storage, away from moisture and light
solubility
125 mg/mL · DMSO : 125 mg/mL (207.12 mM; Need ultrasonic)
form
Solid
pka
5.66 · 5.66±0.50(Predicted)
color
White to off-white
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319
Precautionary statements
501 · P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319
Precautionary statements
P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Chemistry & industry

Applications

UsesGSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research[1].

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
MFCD29770785rac-GSK-F1GSK-F1?orb1306848orb1685569SCHEMBL9953714SCHEMBL30089020SCHEMBL31722834

Database identifiers

CAS
1402345-92-9
PubChem CID
57406702
ChEMBL
CHEMBL3121308